World-first life-changing drug for atherosclerosis cure being produced in Perth is ready for human trials
A world-first drug being developed in WA to cure a disease than can lead to strokes and heart attacks could put a major dent in the annual $14.3 billion cost of cardiovascular disease in Australia.
Atherosclerosis causes a build-up of cholesterol and other fats in the walls of the arteries, making the vessels narrower and more prone to blockage. This in turn increases the risk of stroke, heart attack, kidney failure and more.
Current treatment for atherosclerosis only controls risk factors of the disease but do not offer a cure.
The new drug, ATH01, hopes to offer that cure.
Atherid Therapeutics, founded by Harry Perkins Institute of Medical Research researchers Associate Professor Juliana Hamzah and Professor Shirley Jansen, has received $750,000 in funding to accelerate the production of the drug.
Professor Hamzah invented the drug after discovering a protein that attaches to cells in the arteries, stores cholesterol and fats, and then helps clear the accumulated fats.
'ATH01 targets the root cause by breaking down a build-up of cholesterol and other lipids, offering a transformative solution,' she said.
'(It) combines two powerful molecules. One is based on a natural agent already found in the body, and the other is a 'homing' molecule that zeroes in on cholesterol and fats in the artery walls.'
Professor Jansen said the precise targeting of the drug will ensure it reaches exactly where it's needed.
'It works consistently throughout the entire arterial system, and we understand how it helps the body's cells break down the cholesterol and fatty deposits,' she said.
'If it continues to show success, it could transform the lives of millions.'
Should the drug be successfully produced in its first stage, the duo are set to receive another $750,000 in funding to continue their work.
It's been a long road for the researchers, but after 10 years they have now reached the point where they are ready to move forward towards human trials.
The potentially life-changing treatment could significantly reduce the burden of cardiovascular disease in Australia and abroad.
Across the world, more than 18 million lives are lost annually to cardiovascular disease. More than 42,000 of those are in Australia.
Each year in Australia, more than 57,000 people have heart attacks, more than 38,000 suffer strokes and more than 8000 undergo amputations.
'Our research started from nothing — an unknown, high-risk idea with many doubts about whether it was even possible to clear arteries with a medicine,' Professor Hamzah said.
'Now, we have reached the point where the drug must be manufactured to the highest standards, suitable for patient use, so we can move forward to clinical trials.
'This is an exciting milestone for a new therapy that could dramatically change lives, and it's time to push ahead.'
Harry Perkins Institute boss Professor Peter Leedman said it was an exciting time to see this 'benchmark innovation' being developed and delivered.
'We look forward to witnessing these remarkable advances in clinical research to find better ways to treat and eventually cure atherosclerosis,' he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
West Australian
20 hours ago
- West Australian
West Aussie research breakthrough offers new insight and treatment options for rigid spine syndrome
West Australian researchers have made a breakthrough medical discovery in the fight against a rare genetic muscle disorder. Professor Gina Ravenscroft, head of the Rare Disease Genetics and Functional Genomics group at the Harry Perkins Institute of Medical Research, and Lein Dofash, PhD student at the institute and University of Western Australia Medical School, identified a new genetic cause of rigid spine syndrome. It's a rare muscle disorder that usually presents at birth or in infancy, causing spinal stiffness, muscle weakness and breathing difficulties in children. Most cases are linked to mutations in the SELENON gene, but the latest research found mutations in another gene, HMGCS1. It plays a role in the mevalonate pathway, which is important for muscle function, with HMGCS1 variants causing muscle weakness. The researchers found mutations in five patients from four families with links to spinal rigidity, scoliosis and respiratory issues. 'HMGCS1-related myopathy is a recessive disorder, in all the families,' Professor Ravenscroft said. It means the children with rigid spine syndrome inherited one mutation of the HMGCS1 gene from each healthy parent who doesn't have the disease. They then teamed up with Monash University's Dr Lee Miles and Professor Robert Bryson-Richardson, who are experts in modelling human muscle diseases in the zebrafish, to confirm the finding. 'Zebrafish are an excellent model to study muscle diseases since young zebrafish are see-through and this allows visualisation of the skeletal muscle (which makes up the bulk of the fish tail),' Professor Ravenscroft said. 'Because of the evolutionary conservation between humans and fish, we can model many human diseases in zebrafish in a timely and cost-efficient manner.' It also makes them ideal candidates for testing potential treatments for diseases. The researchers supplemented the fish with mevalonic acid, an important compound in the mevalonate pathway, and found it helped lessen the symptoms of rigid spine syndrome. The significant findings, published in neurology journal Brain, present a new pathway for treatment of the rare disease. 'If we could secure production of clinical-grade mevalonolactone (mevalonic acid), this could potentially be administered on compassionate grounds to patients with HMGCS1-related myopathy,' Professor Ravenscroft said. 'The next step is to identify further patients with HMGCS1-related myopathy to better understand the range of variants that cause disease and the range of clinical presentations that are caused by variants in HMGCS1.'
West Australian
7 days ago
- West Australian
World-first life-changing drug for atherosclerosis cure being produced in Perth is ready for human trials
A world-first drug being developed in WA to cure a disease than can lead to strokes and heart attacks could put a major dent in the annual $14.3 billion cost of cardiovascular disease in Australia. Atherosclerosis causes a build-up of cholesterol and other fats in the walls of the arteries, making the vessels narrower and more prone to blockage. This in turn increases the risk of stroke, heart attack, kidney failure and more. Current treatment for atherosclerosis only controls risk factors of the disease but do not offer a cure. The new drug, ATH01, hopes to offer that cure. Atherid Therapeutics, founded by Harry Perkins Institute of Medical Research researchers Associate Professor Juliana Hamzah and Professor Shirley Jansen, has received $750,000 in funding to accelerate the production of the drug. Professor Hamzah invented the drug after discovering a protein that attaches to cells in the arteries, stores cholesterol and fats, and then helps clear the accumulated fats. 'ATH01 targets the root cause by breaking down a build-up of cholesterol and other lipids, offering a transformative solution,' she said. '(It) combines two powerful molecules. One is based on a natural agent already found in the body, and the other is a 'homing' molecule that zeroes in on cholesterol and fats in the artery walls.' Professor Jansen said the precise targeting of the drug will ensure it reaches exactly where it's needed. 'It works consistently throughout the entire arterial system, and we understand how it helps the body's cells break down the cholesterol and fatty deposits,' she said. 'If it continues to show success, it could transform the lives of millions.' Should the drug be successfully produced in its first stage, the duo are set to receive another $750,000 in funding to continue their work. It's been a long road for the researchers, but after 10 years they have now reached the point where they are ready to move forward towards human trials. The potentially life-changing treatment could significantly reduce the burden of cardiovascular disease in Australia and abroad. Across the world, more than 18 million lives are lost annually to cardiovascular disease. More than 42,000 of those are in Australia. Each year in Australia, more than 57,000 people have heart attacks, more than 38,000 suffer strokes and more than 8000 undergo amputations. 'Our research started from nothing — an unknown, high-risk idea with many doubts about whether it was even possible to clear arteries with a medicine,' Professor Hamzah said. 'Now, we have reached the point where the drug must be manufactured to the highest standards, suitable for patient use, so we can move forward to clinical trials. 'This is an exciting milestone for a new therapy that could dramatically change lives, and it's time to push ahead.' Harry Perkins Institute boss Professor Peter Leedman said it was an exciting time to see this 'benchmark innovation' being developed and delivered. 'We look forward to witnessing these remarkable advances in clinical research to find better ways to treat and eventually cure atherosclerosis,' he said.
The Age
17-05-2025
- The Age
A coroner couldn't tell Danielle how her son died. Then she lost her daughter
Genetic testing is not a mandatory component of coronial investigations into unexplained deaths in any Australian state or territory, and each jurisdiction has its own triggers for including it. For instance, when there is some indication that a gene mutation may have contributed to a death, such as a family history of genetic conditions. This was despite nearly 90 per cent of couples at risk of having a child with a genetic condition having no prior family history of the disorder. The barriers to genetic testing Several state coroners offices and attorneys-general, including in NSW and Victoria, suggested that obtaining consent from next of kin was the main barrier to implementing routine genetic testing. None are updating current guidelines to mandate genetic testing under these circumstances. NSW Attorney-General Michael Daley said a coroner can order genetic testing based on advice from NSW Health Forensic Medicine, and the government was 'always considering ways the coronial process can be improved to provide answers to grieving families'. Loading A spokesperson from the Victorian government said coroners can request the testing 'where it is considered relevant'. Coroners Project co-founder Rachael Casella said even when there is an indication that a genetic condition is at play in a death, instead of conducting genetic testing on the deceased, the coroner or forensic pathologist will often recommend that the family pursue genetic testing for themselves. This requires navigating a complex system, potentially at a personal financial cost. She said placing the burden on grieving families to know about and seek genetic testing is wrong. 'If you're talking to a grieving family, most of the time they're not going to think to go and do genetic testing. They don't know whom to contact … Are there costs involved? Is English their second language?' said Casella, whose daughter Mackenzie died of the genetic condition spinal muscular atrophy at seven months old and is the namesake of federally funded Mackenzie's Mission, a genetic carrier screening trial for would-be parents. Professor Gina Ravenscroft, an expert in rare disease genetics at the Harry Perkins Institute of Medical Research and University of Western Australia, said restricting genetic testing to cases with a family history of genetic conditions was outdated and parents who consent to autopsies are likely to agree to genetic testing because they want to know what killed their loved one. 'I don't see that genetics is that different from any other test we do to try and find out what the cause of death is in an infant or a young person.' Loading Professor Jodie Ingles, head of clinical genomics at the Royal Prince Alfred Hospital, said the cost of genetic testing was likely a deterrent because Medicare does not subsidise it. Forensic pathologists – who order the genetic tests – were also grappling with a backlog of autopsy reports amid a national shortage of the specialists. Kate and Tim Newman lost their two daughters, Olivia and Mia, to heart failure caused by a PPA2 gene mutation before their second birthdays. It was only after Mia died that doctors at the Children's Hospital in Brisbane suggested they test her DNA and a sample kept from Olivia's autopsy. Their experience makes it difficult for them to understand why consent and a lack of resources would be barriers to genetic testing, considering the tens of thousands of dollars it cost the healthcare system and the couple to test and treat their daughters over several distressing months, Kate Newman said. Consenting to the removal of Olivia's brain seemed a far more traumatic request for Newman than if she'd been asked for her consent to do genetic testing, though she said she was never asked. 'To think that there are blockages in terms of funding for genetic tests is crazy … they took my kid's brain out and sent it to America to try and test for certain things, and we didn't need to go through any of that if they'd just done a blood test and got DNA results,' she said. Guilt, false accusations and the relief of a diagnosis Finding answers helped the Greens and Newmans with the overwhelming guilt attached to the sudden and unexplained deaths of multiple children. 'I was addicted to googling rabbit holes, reading every article, medical journal, anything I could get my hands on,' Danielle Green said. 'I just held so much guilt. Did I not take gastro seriously enough? Did I allow him to get dehydrated? Was he showing symptoms of this months prior?' Carola Vinuesa, a professor in immunology and genetics at the Francis Crick Institute in London, who was part of a team that analysed Kathleen Folbigg's DNA for genetic mutations, said having a diagnosis can also stop parents being wrongly accused of harming their children, especially when there is more than one child death in the family. 'Every post-mortem in a child should have a genetic test,' Vinuesa said. Loading Newman said she was questioned by detectives and child protection service officers after Mia's death. 'We were saying goodbye to Mia, we had her in the hospital room, and we got pulled out by a detective and child services,' Newman said, becoming upset as she retells the story. 'They're protecting the children, but I must say that was really tough to be questioned. I remember he said 'Children don't just die' and I took great offence to that. 'I hate to think that there's anyone else out there who's lost a child and doesn't have answers. The guilt that they may feel, not having known, and the potential that it could happen again.' There are some signs of progress towards better integrating genetic testing. WA's Health Minister, Amber-Jade Sanderson, foreshadowed updating the state's model of care for unexpected deaths in young people, and South Australian Women's and Children's Health Network is leading a national genetic autopsy study using genomic sequencing to better understand the causes of pregnancy loss. The Coroners Project is supported by several organisations, including Murdoch Children's Research Institute, Red Nose Australia, Australian Genomics and Mito Foundation.
